T. Rowe Price Health Sciences Fund I Class
THISX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 East Pratt Street Baltimore MD United States of America 21202
- IPO Date
- Mar 24, 2016
- CIK
- 0001002624
- Website
- troweprice.com
- Similar Companies
- Business
- T. Rowe Price Health Sciences Fund I Class (THISX) is an open-end mutual fund that seeks long-term capital appreciation by investing at least 80% of its net assets in common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences, including pharmaceuticals, health care services, medical products and devices, and biotechnology firms; the fund primarily targets large- and mid-capitalization companies but may invest across all market caps, including foreign stocks, private placements, and initial public offerings, with a portfolio turnover rate of approximately 52% and total net assets exceeding $11 billion. Primarily serving institutional investors with a $500,000 minimum initial investment, THISX employs fundamental bottom-up analysis blending growth and value strategies to identify high-quality companies developing innovative medicines or improving health care efficiency; key holdings as of recent data include Eli Lilly and Co. (8.71%), Intuitive Surgical Inc. (4.75%), Stryker Corp. (4.58%), argenx SE (4.57%), and aggregate miscellaneous equity (8.82%), with over 88% allocated to the health care sector and roughly 82% to U.S. stocks. The fund, domiciled in the United States and available for sale there, is managed by T. Rowe Price Associates, Inc., headquartered at 100 East Pratt Street, Baltimore, Maryland, with the I Class launched on March 23, 2016. Recent major changes include a temporary portfolio manager transition effective March 24, 2025, when chair Ziad Bakri commenced sabbatical, with Jason Nogueira assuming interim responsibilities as portfolio manager and committee chair until Bakri's expected return around July 17, 2025; this follows T. Rowe Price Group's strategic collaboration announced September 4, 2025, with Goldman Sachs to develop diversified public and private market solutions for retirement and wealth channels, including Goldman Sachs' intended $1 billion investment in T. Rowe Price common stock. In December 2025, the firms launched co-branded model portfolios as part of this alliance, amid T. Rowe Price Group's reported preliminary assets under management of $1.79 trillion as of November 30, 2025.